CJC-1295 NO DAC 10MG

$39.99

CJC-1295 NO DAC 10mg (99% purity). Lyophilized peptide in a sterile, sealed vial for controlled laboratory research. Diluent not included. For research use only โ€” not for human consumption.

๐Ÿงช Third-Party Lab Tested โ€“ Freedom Diagnostics

Product: CJC-1295 NO DAC 10mg
Batch: CJCND102511
Accession / COA #: 2601280011
๐Ÿ“„ View COA (Direct PDF)

๐Ÿ” Verify COA on Freedom Diagnostics

How to verify authenticity:
1. Open the Freedom Diagnostics link above.
2. Enter accession number 2601280011 into the search bar.
3. Select the file Iron2601280011.pdf to view the official COA.

Availability: In stock

SKU: CJCNDAC10 Category:

IRON AMINOS CJC-1295 NO DAC 10MG

Research-grade GHRH-pathway material prepared for consistency and clean documentation in professional lab workflows.

Key Features

 

  • 10mg CJC-1295 NO DAC per vial (lyophilized powder)

  • โ‰ฅ99% purity for reproducible results

  • Sterile, sealed glass vial with tamper-evident flip cap

  • Lot/batch labeling for traceability

  • Signature Iron Aminos red-honeycomb label for quick identification

  • Diluent not included

 

Specifications

 

  • Compound: CJC-1295 (NO DAC), a short-acting GHRH(1-29) analog (often referred to in research as Mod GRF(1-29))

  • Pathway: Growth hormoneโ€“releasing hormone (GHRH) receptor agonist research category

  • Form / Appearance: Lyophilized powder, white/off-white

  • Amount: 10mg per vial

  • Purity: โ‰ฅ99%

  • Storage (lyophilized): Cool, dry place away from light

  • Storage (after reconstitution): Refrigerate; use promptly per internal SOP

 

Whatโ€™s Included

 

  • 1 ร— CJC-1295 NO DAC 10mg vial (no diluent)

 

Handling

 

Use an appropriate sterile diluent and aseptic technique. Follow your labโ€™s SOPs for reconstitution, aliquoting, labeling, and disposal.

Research Snapshot

 

  • Short-acting GHRH analogs like CJC-1295 NO DAC have been studied for transient stimulation of growth hormone (GH) secretion and enhancement of pulsatile GH release, often with associated increases in IGF-1in early human and animal studies.

  • Compared with long-acting DAC-modified versions, NO DAC exhibits a shorter half-life, supporting pulsatile GH profiles in protocol designs.

  • Reported study adverse effects for this class include injection-site reactions, transient flushing, and mild GI symptoms; findings are protocol-dependent.

  • This compound remains investigational; evidence is context-specific and continues to evolve.

 

Compliance

 

For research use only. Not for human consumption.

Not a drug, food, or cosmetic and not intended to diagnose, treat, cure, or prevent any disease.

Shopping Cart
Scroll to Top